---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-26-000015"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:51:36.165073+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q1 2026 net loss $9.0M; cash $118.3M; GBM trial dosed first patient

## Summary
- Net loss of $9.0M vs net income of $56.5M in Q1 2025 (prior year included license revenue).
- Cash, cash equivalents, and investments $118.3M as of March 31, 2026; sufficient into 2H 2028.
- R&D expenses $7.0M (down from $10.5M); G&A expenses $4.3M (down from $5.0M).
- First patient dosed in Phase 2 trial of silevertinib + temozolomide for newly diagnosed EGFRvIII+ GBM.
- Oral presentation of silevertinib Phase 2 frontline NSCLC data at ASCO 2026 on May 30.

## SEC filing metadata
- accession: 0001701541-26-000015
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/0001701541-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/bdtx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-26-000015
- JSON: https://secwatch.observer/filing/0001701541-26-000015.json
- Plain text: https://secwatch.observer/filing/0001701541-26-000015.txt

## Source-grounded claims
- claim_id: f77029317e0c1d9579ab57aeaff75780758e7e4f
  claim: Black Diamond Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $9.0 million.
  evidence_excerpt: Net loss for the first quarter of 2026 was $9.0 million, as compared to net income of $56.5 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000015/0001701541-26-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.